Alembic Pharmaceuticals Limited
NSE: APLLTD BSE: APLLTD
NSE
899.80
-1.95 (-0.22%)
Prev Close
901.75
Open Price
897
Volume
62,002
Today Low / High
891.1 / 905
52 WK Low / High
725.2 / 1123.95
Range
855 - 945
BSE
899.90
-2.30 (-0.25%)
Prev Close
902.2
Open Price
896.05
Volume
3,839
Today Low / High
890.8 / 904.9
52 WK Low / High
725.6 / 1122.4
Range
855 - 945
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 899.8 (target range: 855 - 945), reflecting a change of -1.95 (-0.21625%). On the BSE, it is listed at 899.9 (target range: 855 - 945), showing a change of -2.3 (-0.25493%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
05 Dec
897.00
0.31%
04 Dec
892.30
1.06%
03 Dec
900.20
1.03%
02 Dec
900.20
1.03%
01 Dec
907.70
-0.83%
30 Nov
909.40
-0.19%
28 Nov
905.30
0.21%
27 Nov
905.30
0.21%
26 Nov
906.00
0.97%
25 Nov
885.70
2.20%
24 Nov
903.70
0.01%
21 Nov
894.20
0.76%
19 Nov
911.10
-0.53%
18 Nov
945.05
-3.33%
17 Nov
919.95
3.14%
14 Nov
915.95
-1.30%
13 Nov
916.65
-0.08%
12 Nov
917.00
-0.04%
11 Nov
923.55
-0.71%
10 Nov
923.95
0.29%
Alembic Pharmaceuticals Limited Graph
Alembic Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 899.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 899.90 | 908.90 | 818.01 - 999.79 |
| 917.90 | 734.32 - 1,101.48 | ||
| 926.90 | 648.83 - 1,204.97 | ||
| Bearish Scenario | 899.90 | 890.90 | 801.81 - 979.99 |
| 881.90 | 705.52 - 1,058.28 | ||
| 872.90 | 611.03 - 1,134.77 |
Overview of Alembic Pharmaceuticals Limited
ISIN
INE901L01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
182,175
Market Cap
176,867,498,975
Last Dividend
11
Official Website
IPO Date
2011-09-20
DCF Diff
-51.64
DCF
951
Financial Ratios Every Investor Needs
Stock Dividend of APLLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-29 | July 29, 25 | 11 | 11 | 2025-07-29 | 2025-08-07 | |
| 2024-07-15 | July 15, 24 | 11 | 11 | 2024-07-15 | 2024-08-21 | |
| 2023-07-28 | July 28, 23 | 8 | 8 | 2023-07-28 | 2023-09-03 | |
| 2022-08-17 | August 17, 22 | 10 | 10 | 2022-08-18 | 2022-09-03 | |
| 2021-07-19 | July 19, 21 | 14 | 14 | 2021-07-20 | 2021-07-31 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,672.07 Cr | 1,880.76 Cr | 4,791.31 Cr | 0.7181 | 521.91 Cr | 0.00 Cr | 2,701.75 Cr | 583.42 Cr | 29.68 | 989.11 Cr | 0.0874 |
| 2024-03-31 | 6,228.63 Cr | 1,796.12 Cr | 4,432.51 Cr | 0.7116 | 474.92 Cr | 0.00 Cr | 2,508.44 Cr | 615.82 Cr | 31.33 | 914.08 Cr | 0.0989 |
| 2023-03-31 | 5,652.62 Cr | 1,774.78 Cr | 3,877.84 Cr | 0.6860 | 721.84 Cr | 0.00 Cr | 1,980.52 Cr | 341.99 Cr | 17.40 | 696.16 Cr | 0.0605 |
| 2022-03-31 | 5,305.79 Cr | 1,498.21 Cr | 3,807.58 Cr | 0.7176 | 838.46 Cr | 0.00 Cr | 1,830.88 Cr | 520.94 Cr | 26.50 | 858.50 Cr | 0.0982 |
| 2021-03-31 | 5,393.13 Cr | 1,340.21 Cr | 4,052.92 Cr | 0.7515 | 670.00 Cr | 0.00 Cr | 2,331.56 Cr | 1,146.50 Cr | 59.18 | 1,466.31 Cr | 0.2126 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.10 Cr | 7,772.94 Cr | 2,583.42 Cr | 5,190.9400 Cr | 1,257.50 Cr | 1,167.40 Cr | 2,288.14 Cr | 3,360.76 Cr | 0.00 Cr | 0.00 Cr | 127.21 Cr | 2,412.3300 Cr |
| 2024-03-31 | 120.21 Cr | 6,445.58 Cr | 1,627.38 Cr | 4,818.2000 Cr | 513.16 Cr | 392.95 Cr | 1,643.54 Cr | 3,071.05 Cr | 0.00 Cr | -131.28 Cr | 93.02 Cr | 1,455.0000 Cr |
| 2023-03-31 | 75.48 Cr | 6,182.83 Cr | 1,812.36 Cr | 4,370.4700 Cr | 722.02 Cr | 646.54 Cr | 1,475.27 Cr | 2,999.73 Cr | 218.79 Cr | -83.14 Cr | 96.33 Cr | 1,636.9300 Cr |
| 2022-03-31 | 61.09 Cr | 7,122.03 Cr | 1,884.48 Cr | 5,237.5500 Cr | 717.11 Cr | 656.02 Cr | 1,609.70 Cr | 3,947.26 Cr | 69.22 Cr | -197.69 Cr | 118.40 Cr | 1,716.5300 Cr |
| 2021-03-31 | 98.06 Cr | 6,708.98 Cr | 1,642.01 Cr | 5,066.9600 Cr | 583.61 Cr | 485.55 Cr | 1,486.15 Cr | 3,648.03 Cr | 299.87 Cr | 85.52 Cr | 49.31 Cr | 1,280.8400 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 87.9700 Cr | -568.4100 Cr | 443.7100 Cr | -475.6500 Cr | -36.7300 Cr | 83.4800 Cr | -563.6200 Cr | 583.4200 Cr | 765.1200 Cr | -216.2200 Cr | -644.6000 Cr |
| 2024-03-31 | 803.2000 Cr | -320.6100 Cr | -437.8700 Cr | 475.7300 Cr | 44.7300 Cr | 120.2100 Cr | -327.4700 Cr | 615.8200 Cr | -205.4100 Cr | -157.2500 Cr | -168.2800 Cr |
| 2023-03-31 | 723.9500 Cr | -447.5900 Cr | -261.9600 Cr | 280.5400 Cr | 14.3900 Cr | 75.4800 Cr | -443.4100 Cr | 354.5900 Cr | 5.8700 Cr | -196.5600 Cr | 134.4400 Cr |
| 2022-03-31 | 552.3500 Cr | -371.9700 Cr | -217.3500 Cr | 126.7100 Cr | -36.9700 Cr | 61.0900 Cr | -425.6400 Cr | 620.1100 Cr | 129.9800 Cr | -275.1900 Cr | -123.5500 Cr |
| 2021-03-31 | 1,463.3800 Cr | -838.8100 Cr | -597.4300 Cr | 803.8700 Cr | 26.2200 Cr | 98.0600 Cr | -659.5100 Cr | 1,368.0800 Cr | -1,239.7500 Cr | 0.0000 Cr | -298.6200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,910.15 Cr | 1,029.53 Cr | 880.62 Cr | 0.4610 | 239.62 Cr | 184.71 Cr | 9.40 | 322.60 Cr | 0.0967 |
| 2025-06-30 | 1,710.72 Cr | 407.41 Cr | 1,303.31 Cr | 0.7618 | 880.54 Cr | 154.38 Cr | 7.85 | 272.41 Cr | 0.0902 |
| 2025-03-31 | 1,769.62 Cr | 618.02 Cr | 1,151.60 Cr | 0.6508 | 230.79 Cr | 156.89 Cr | 7.98 | 267.89 Cr | 0.0887 |
| 2024-12-31 | 1,692.75 Cr | 439.54 Cr | 1,253.21 Cr | 0.7403 | 855.69 Cr | 138.42 Cr | 7.01 | 253.53 Cr | 0.0818 |
| 2024-09-30 | 1,647.98 Cr | 429.12 Cr | 1,218.86 Cr | 0.7396 | 827.39 Cr | 153.41 Cr | 7.79 | 238.53 Cr | 0.0931 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 143.03 Cr | 12.15 Cr | 155.18 Cr | 1,313.93 Cr | 2,540.70 Cr | 4,349.68 Cr | 3,514.73 Cr | 8,396.93 Cr | 3,080.91 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 83.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -5,189.52 Cr |
| 2025-03-31 | 90.10 Cr | 0.00 Cr | 90.10 Cr | 1,399.79 Cr | 2,288.14 Cr | 4,087.80 Cr | 3,360.76 Cr | 7,772.94 Cr | 2,583.42 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 128.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,887.64 Cr |
| 2024-09-30 | 122.05 Cr | 27.22 Cr | 149.27 Cr | 1,267.68 Cr | 2,012.52 Cr | 3,762.39 Cr | 3,124.86 Cr | 7,230.25 Cr | 2,342.61 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 154.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 156.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 138.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 153.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 134.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,805.30 | ₹4,331,519,421,341.00 | ₹1,777,326.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,473.50 | ₹1,718,510,852,630.00 | ₹148,896.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,785.90 | ₹1,281,320,591,296.00 | ₹197,200.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,275.20 | ₹1,061,619,971,880.00 | ₹1,036,022.00 |
| Lupin Limited | LUPIN | ₹2,098.80 | ₹958,652,463,384.00 | ₹971,777.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹931.45 | ₹937,256,649,986.00 | ₹892,133.00 |
| Mankind Pharma Limited | MANKIND | ₹2,205.50 | ₹910,441,577,474.00 | ₹299,676.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,217.60 | ₹707,184,056,165.00 | ₹394,502.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,675.50 | ₹678,591,157,500.00 | ₹117,812.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,968.20 | ₹555,427,632,274.00 | ₹420,803.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,026.10 | ₹553,946,838,790.00 | ₹936,825.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,459.10 | ₹370,179,824,484.00 | ₹237,709.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,640.60 | ₹329,905,008,734.00 | ₹83,792.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,825.40 | ₹285,945,259,200.00 | ₹124,871.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,396.20 | ₹264,670,439,381.00 | ₹122,772.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,226.50 | ₹230,662,500,000.00 | ₹4,345.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,360.00 | ₹220,989,349,840.00 | ₹5,339,760.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,887.00 | ₹216,658,335,543.00 | ₹31,420.00 |
| Eris Lifesciences Limited | ERIS | ₹1,551.70 | ₹211,367,749,765.00 | ₹55,130.00 |
| Cohance Lifesciences Limited | COHANCE | ₹542.55 | ₹207,561,801,807.00 | ₹345,765.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹899.80 | ₹176,867,498,975.00 | ₹62,002.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,073.70 | ₹170,179,769,660.00 | ₹78,154.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹933.60 | ₹167,216,974,632.00 | ₹837,870.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,963.40 | ₹149,241,363,926.00 | ₹58,334.00 |
| Granules India Limited | GRANULES | ₹560.85 | ₹136,100,749,369.00 | ₹2,352,896.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹883.75 | ₹108,419,641,295.00 | ₹184,086.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,713.00 | ₹94,832,269,366.00 | ₹6,387.00 |
| Strides Pharma Science Limited | STAR | ₹880.65 | ₹81,171,900,584.00 | ₹127,025.00 |
| FDC Limited | FDC | ₹414.05 | ₹67,411,515,280.00 | ₹43,781.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹721.55 | ₹65,406,554,986.00 | ₹143,806.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹331.65 | ₹64,864,709,276.00 | ₹102,130.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹420.00 | ₹64,302,864,360.00 | ₹79,095.00 |
| Sequent Scientific Limited | SEQUENT | ₹199.70 | ₹49,889,816,654.00 | ₹2,136,131.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.94 | ₹49,632,331,669.00 | ₹15,943,807.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹867.70 | ₹44,008,967,409.00 | ₹52,567.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹377.35 | ₹41,118,042,748.00 | ₹113,614.00 |
| Innova Captab Limited | INNOVACAP | ₹708.30 | ₹40,532,417,211.00 | ₹6,208.00 |
| Suven Life Sciences Limited | SUVEN | ₹170.18 | ₹37,508,695,633.00 | ₹265,127.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹405.00 | ₹36,964,350,000.00 | ₹151,590.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,201.00 | ₹36,402,372,015.00 | ₹4,548.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹355.40 | ₹35,640,402,632.00 | ₹30,343.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹445.55 | ₹31,369,281,913.00 | ₹4,826.00 |
| Hikal Limited | HIKAL | ₹243.14 | ₹29,979,344,355.00 | ₹3,724,882.00 |
Key Executives
Executive Director
Mr. Raj Kumar Shreeram Baheti B.Com.(Hon.), FCA, FCS
Gender: male
Year Born: 1959
Chief Scientific Officer
Dr. J. Venkat Raman M. S., Ph.D.
Gender: Not Specified
Year Born: 1958
Executive Chairman & Chief Executive Officer
Mr. Chirayu Ramanbhai Amin
Gender: male
Year Born: 1946
Chief Financial Officer
Mr. G. Krishnan
Gender: male
Year Born:
MD & Executive Director
Mr. Pranav Chirayu Amin
Gender: male
Year Born: 1975
Senior Vice President of SCM & Operations
Dr. Sachin Ghosalkar
Gender: Not Specified
Year Born:
Head-Legal & Taxation
Mr. Amresh Choudhary
Gender: male
Year Born:
Chief Business Development Officer
Mr. Udit C. Amin
Gender: male
Year Born: 1980
MD & Executive Director
Mr. Shaunak Chirayu Amin
Gender: male
Year Born: 1978
Company Secretary & Compliance Officer
Ms. Manisha Saraf
Gender: female
Year Born:
FAQs about Alembic Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Chirayu Ramanbhai Amin.
What is the current market price of the stock?
The current price is ₹899.80.
What is the 52-week price range?
The range is ₹725.2-1123.95.
What is the market capitalization of the company?
The market capitalization is ₹17,686.75 crores.
What is the dividend yield?
The dividend yield is 1.22%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 27.88.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Pharmaceuticals Limited (ISIN: INE901L01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹17,686.75 crores and an average daily volume of 182,175 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.